The term 'neuroendocrine neoplasms' (NEN) covers a wide range of tumors originating from neuroendocrine cells in various organs. Heterogeneity and rarity of NEN have hampered early diagnosis and standardized treatment for years, with many physicians being unaware of the clinical relevance of NEN. Although expanding knowledge of the molecular characteristics of neuroendocrine cells resulted in new diagnostic and therapeutic possibilities, their integration into management algorithms is still ongoing. Furthermore, availability of diagnostic and therapeutic tools varies considerably in different regions of the world.
aspects in the current management of neuroendocrine neoplasms, written from individual experts in their specific field to assist clinicians involved in the daily care of NEN who may be somehow overwhelmed by the large number of published guidelines.
Guido Rindi and his co-authors start with their perspective on histology of NEN in their paper CYTO-HISTOLOGY IN NET: WHAT IS NECESSARY TODAY AND WHAT IS THE FUTURE? [89] . Matthias M. Weber and co-authors discuss the endocrine evaluation of functioning NEN in their paper HORMONE SECRETING GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASIAS (GEP-NEN ): WHEN TO CO NSIDER, HOW TO DIAGNOSE? [90] . Javier G. Castillo and co-authors give us some insight on diagnostic evaluation of carcinoid heart disease in their paper ECHOCARDIOGRAPHY IN F U N C T I O N A L M I D G U T N E U R O E N D O C R I N E TUMORS: WHEN AND HOW OFTEN? [91] . As localization of the primary tumor in patients with proven NEN is sometimes difficult, Gregory A. Kaltsas and his group present a n o v e r v i e w o n t h e M A N A G E M E N T O F NEUROENDOCRINE TUMORS OF UNKNOWN PRIMARY [92] . With many guidelines initially focusing in NEN of the gastrointestinal tract, pulmonary NEN were somehow neglected, but Robert A. Ramirez and co-authors update u s o n t h e M A N A G E M E N T O F P U L M O N A RY NEUROENDOCRINE TUMORS [93] . Moving to new aspects of treatment, Ernst von Dobschuetz and co-authors answer the question IS THERE ANY RO LE FO R MINIMALLY INVASIVE SURGERY IN NET? [94] . With the frequent occurrence of liver metastases, Philippe Ruszniewski and co-authors present their view on LIVER TRANSARTERIAL EMBOLIZATIONS IN METASTATIC NEUROENDOCRINE TUMORS [95] , and Vincenzo Mazzaferro and co-authors discuss THE PLACE OF LIVER TRANSPLANTATION IN THE TREATMENT OF HEPATIC METASTASES FROM NEUROENDOCRINE TUMORS: PROS AND CONS [96] . Although the low proliferation rate in the majority of NEN and the possibility of specific treatments such as biotherapy and PRRT leaves a somehow smaller role for chemotherapy, certain types of NEN may require such an approach, and therefore Ashley Grossman and co-authors answer the question CHEMOTHERAPY IN NETs: WHEN AND HOW [97] . As NEN may occur as part of multiple endocrine neoplasia syndromes with important consequences for the patient and family members, Triona O'Shea and Maralyn Druce discuss WHEN SHOULD GENETIC TESTING BE PERFORMED IN PATIENTS WITH NEUROENDOCRINE TUMOURS? [98] . Finally, it is less known, that Merkel cell carcinoma is a skin cancer with a neuroendocrine phenotype, and Claus Garbe and co-authors enlighten us on similarities and differences in their article MERKEL CELL CARCINOMA: EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS AND THERAPY [99] .
We hope that this first part of 2 issues of this journal devoted to the management of NEN will provide you with the most up-to-date information on key areas in the management of NEN. We are thankful to our colleagues across the world for summarizing their vast experience, and look forward to give you further insight into this orphan disease form which still poses a major challenge to the caring physician.
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